FOLFOX
Lilly’s pegilodecakin combo falls at Phase 3 in pancreatic cancer
October 17, 2019Research and Development Cancer, Eli Lilly, FOLFOX, Pancreatic cancer, pegilodecakin, pharma
In disappointing news, Eli Lilly has revealed that pegilodecakin, in combination with the chemotherapy regimen FOLFOX (Folinic acid, Fluorouracil and …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
